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Evaluation of the inhibition potential 
of plumbagin against cytochrome 
P450 using LC-MS/MS and cocktail 
approach
Ang Chen1,*, Xiaojing Zhou1,*, Shuowen Tang1, Mingyao Liu1,2 & Xin Wang1
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), a natural naphthoquinone compound isolated 
from roots of Plumbago zeylanica L., has drawn a lot of attention for its plenty of pharmacological 
properties including antidiabetes and anti-cancer. The aim of this study was to investigate the effects 
of plumbagin on CYP1A2, CYP2B1/6, CYP2C9/11, CYP2D1/6, CYP2E1 and CYP3A2/4 activities in 
human and rat liver and evaluate the potential herb-drug interactions using the cocktail approach. All 
CYP substrates and their metabolites were analyzed using high-performance liquid chromatography–
tandem mass spectrometry (LC-MS/MS). Plumbagin presented non-time-dependent inhibition of CYP 
activities in both human and rat liver. In humans, plumbagin was not only a mixed inhibitor of CYP2B6, 
CYP2C9, CYP2D6, CYP2E1 and CYP3A4, but also a non-competitive inhibitor of CYP1A2, with Ki values 
no more than 2.16 μM. In rats, the mixed inhibition of CYP1A2 and CYP2D1, and competitive inhibition 
for CYP2B1, CYP2C11 and CYP2E1 with Ki values less than 9.93 μM were observed. In general, the 
relatively low Ki values of plumbagin in humans would have a high potential to cause the toxicity and 
drug interactions involving CYP enzymes.
Plumbago zeylanica L. (family: Plumbaginaceae), also known as Chitrak, is a medicinal plant and mainly distrib-
uted around Africa and Asia including India and China1,2. It is originally documented in “Tang Ben Cao” in China 
and widely used in prescription for treating many diseases such as rheumatic joint pain, blood stasis amenorrhea 
and malignant sore in Traditional Chinese medicine3. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone, 
Fig. 1a) isolated from roots of Plumbago zeylanica L. is an active naphthoquinone and responsible for its therapeu-
tic effects4. Previous studies have reported that plumbagin possesses lots of pharmacological properties includ-
ing antidiabetic, anti-inflammatory, antibacterial and anti-immediate allergic reaction activities1,5. In particular, 
plumbagin presents significant anticancer activity6. For example, plumbagin can induce apoptosis and autophagy 
of human prostate cancer cells via sirtuin1- and PI3K/Akt/mTOR-mediated pathways7. And it also can kill human 
gastric cancer cells by induction of SH2-containing protein tyrosine phosphatase 18. Therefore, Plumbagin is 
considered to be a promising antitumor candidate for drug development.
The cytochrome P450 (CYP) enzymes play an important role in metabolism of xenobiotics and endogenous 
substances. Almost 90% drugs are metabolized by CYP superfamily9,10. Among the CYP isoforms identified, the 
major human CYP isoforms (CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4) are responsible for 
80% of the CYP-mediated metabolism11–13. However, the inhibition and induction of CYP by herbs often occur, 
which is directly linked to herb-drug interactions (HDIs) and result in the toxicity and/or therapeutic failure14,15. 
In consequence, U.S. Food and Drug Administration (FDA) has recommended to use CYP-associated metabolic 
studies in vitro to predict the potential HDIs, which is the major attrition in drug development16. Recently, one 
study only found the inhibitory effects of plumbagin on CYP1A2, CYP2C19 and CYP3A417. However, the mech-
anisms of CYP inhibition remain unclear. Further studies should be carried out to illustrate the mechanisms of 
plumbagin on CYP enzymes.
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The aim of this study was to investigate the effects of plumbagin on several major CYP activities both in 
human and rat liver, including CYP1A2, CYP2B1/6, CYP2C9/11, CYP2D1/6, CYP2E1 and CYP3A2/4, and fur-
ther explore the mechanisms of plumbagin on CYP inhibitory properties. In this report, the cocktail approach 
using classical substrates including phenacetin (CYP1A2), bupropion (CYP2B1/6), tolbutamide (CYP2C9/11), 
Figure 1. Chemical structure of plumbagin (a) and the inhibitory effects of CYPs activities by plumbagin 
in pooled human liver microsomes (b) and pooled rat liver microsomes (c). Chemical structure was 
produced using ChemDraw Professional 15.0. Results were mean ± SD of quadruplicate assays. The data was fit 
to log (plumbagin concentration) and normalized response equations using GraphPad Prism 5.0.
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dextromethorphan (CYP2D1/6), chlorzoxazone (CYP2E1) and midazolam (CYP3A2/4)16, alternatively named 
the n-in-one assay, was adopted to monitor several CYP activities in a single experiment, which was much com-
prehensive, time and resource efficient10,18. In this approach, a liquid chromatography tandem mass spectrometry 
(LC-MS/MS) was usually used for the simultaneous detection of the formation of metabolites of these probe sub-
strates to calculate the enzymatic reaction rates, which could be used to evaluate the corresponding CYP enzyme 
activities19. To our knowledge, this is the first study to report the potential effects of plumbagin on CYP2B1/6, 
CYP2C9/11, CYP2E1 and CYP2D1/6, and demonstrate the inhibitory mechanisms of CYPs. Therefore, the pres-
ent study could be helpful to evaluate the potential HDIs involved with plumbagin comprehensively.
Results
Inhibition effects of plumbagin on CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 
activities in human liver. To investigate the effects of plumbagin on human CYP activities, various concen-
trations of plumbagin ranging from 0.05 μ M to 50 μ M were used to determine IC50 (Fig. 1b). Plumbagin inhibited 
CYP1A2-catalyzed phenacetin O-deethylation, CYP2B6-catalyzed bupropion hydroxylation, CYP2C9-catalyzed 
tolbutamide methyl-hydroxylation, CYP2D6-catalyzed dextromethorphan O-demethylation, CYP2E1-catalyzed 
chlorzoxazone 6-hydroxylation and CYP3A4-catalyzed midazolam 1-hydroxylation with IC50 values at 7.49 μ M, 
13.10 μ M, 10.94 μ M, 10.21 μ M, 6.54 μ M and 6.45 μ M in HLMs, respectively (Table 1). These data certificated that 
plumbagin exhibited potently inhibitory effects on the major human six CYPs, including CYP1A2, CYP2B6, 
CYP2C9, CYP2D6, CYP2E1 and CYP3A4.
Inhibition effects of plumbagin on CYP1A2, CYP2B1, CYP2C11, CYP2D1, CYP2E1 and CYP3A2 
activities in rat liver. In rat liver, plumbagin also inhibited CYP1A2-catalyzed phenacetin O-deethylation, 
CYP2B1-catalyzed bupropion hydroxylation, CYP2C11-catalyzed tolbutamide methyl-hydroxylation, 
CYP2D1-catalyzed dextromethorphan O-demethylation, CYP2E1-catalyzed chlorzoxazone 6-hydroxylation and 
CYP3A2-catalyzed midazolam 1-hydroxylation with IC50 values at 2.65 μ M, 5.86 μ M, 3.85 μ M, 6.17 μ M, 3.72 μ M 
and 8.47 μ M, respectively (Table 1). In brief, plumbagin strongly inhibited all selected CYP-catalyzed probe reac-
tions in a concentration-dependent manner (Fig. 1c), which agreed with the data of humans.
Enzyme kinetic analysis for inhibition of CYPs by plumbagin in human liver. To investi-
gate whether the inhibition of CYPs by plumbagin was time-dependent, CYP activities were determined by 
pre-incubating microsomal incubation mixtures with NADPH for 0, 5, 10 and 20 min at 37 °C. Plumbagin 
showed no apparent time-dependent inhibition on all CYPs (CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1 
and CYP3A4) (Fig. 2).
To further determine the types of CYP inhibition by plumbagin in HLMs, enzyme kinetics studies were car-
ried out with various substrates concentrations in the presence or absence of plumbagin. The Lineweaver-Burk 
transformation of the enzyme velocities versus substrates concentrations showed that the types of inhibition by 
plumbagin for these selected CYPs were mixed inhibition on CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4, 
but non-competitive for CYP1A2. The Ki values were determined using the secondary Lineweaver–Burk plot, 
and then calculated at 0.15 μ M, 1.62 μ M, 2.16 μ M, 1.46 μ M, 0.65 μ M and 0.88 μ M for CYP1A2, CYP2B6, CYP2C9, 
CYP2D6, CYP2E1 and CYP3A4, respectively. From the secondary plot of Lineweaver–Burk plot for α Ki, α Ki 
values were 0.16 μ M, 2.92 μ M, 1.46 μ M, 2.22 μ M, 2.64 μ M and 0.57 μ M for CYP1A2, CYP2B6, CYP2C9, CYP2D6, 
CYP2E1 and CYP3A4, respectively. Since α values of CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 were 
not equal to 1, the types of inhibition by plumbagin for these five CYPs were mixed inhibition. However, the type 
of inhibition by plumbagin for CYP1A2 was non-competitive inhibition due to α value of CYP1A2 approximately 
equal to 1 (Table 1, Fig. 3).
Enzyme kinetic analysis for inhibition of CYPs by plumbagin in rat liver. The time-dependent inhi-
bition experiments were also performed and no time-dependent inhibition was observed in RLMs (Fig. 2). The 
Lineweaver-Burk transformation of the enzyme velocities versus substrates concentrations showed that the types 
CYP isoform IC50 (μM) Ki (μM) αKi (μM) α Type
Humans
1A2 7.49 0.15 0.16 0.94 non-competitive
2B6 13.10 1.62 2.92 0.55 mixed-type
2C9 10.94 2.16 1.46 1.48 mixed-type
2D6 10.21 1.46 2.22 0.66 mixed-type
2E1 6.54 0.65 2.64 0.25 mixed-type
3A4 6.45 0.88 0.57 1.54 mixed-type
Rats
1A2 2.65 2.64 8.51 0.31 mixed-type
2B1 5.86 9.93 ‒ ‒ competitive
2C11 3.85 7.85 ‒ ‒ competitive
2D1 6.17 9.49 13.79 0.69 mixed-type
2E1 3.72 6.28 ‒ ‒ competitive
3A2 8.47 ‒ ‒ ‒ atypical kinetics
Table 1.  Inhibitory effects of plumbagin on six CYP isoforms in HLMs and RLMs.
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of inhibition by plumbagin for these selected CYPs were mixed inhibition on CYP1A2 and CYP2D1, but compet-
itive for CYP2B1, CYP2C11 and CYP2E1. The Ki values were calculated to be 2.64 μ M, 9.93 μ M, 7.85 μ M, 9.49 μ M 
and 6.28 μ M for CYP1A2, CYP2B1, CYP2C11, CYP2D1 and CYP2E1, respectively. From the secondary plot of 
Lineweaver-Burk plot for α Ki, α Ki values were 8.51 μ M and 13.79 μ M for CYP1A2 and CYP2D1, respectively. The 
types of inhibition by plumbagin on CYP1A2 and CYP2D1 were mixed inhibition, because α values of CYP1A2 
and CYP2D1 were not equal to 01 (Table 1, Fig. 4). Moreover, the enzyme inhibition kinetics of CYP3A2 did not 
conform to the classical Michaelis–Menten kinetics (Fig. 5), which would be discussed in Discussion section.
Figure 2. Time- and concentration-dependent inhibition of human and rat liver microsomal CYPs. The 
figures were prepared by a semilogarithmic plot of percent remaining activity vs incubation time. Microsomal 
reaction mixtures were pre-incubated for 20 min without (⚫) or with plumbagin at 0.5 μ M ( ), 1 μ M ( ),  
2 μ M ( ) in humans or plumbagin at 0.2 μ M ( ), 0.5 μ M ( ), 1 μ M ( ) in rats. Each data point represents the 
mean of quadruplicate determinations.
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Figure 3. Primary Lineweaver–Burk plot, the secondary plot for Ki and the secondary plot for αKi in the 
inhibition of CYP-mediated probe substrate metabolism by various concentrations of plumbagin (0 , 1 , 
2 , 5 , 10♦ μM) in pooled human liver microsomes. Phenacetin was used at concentrations of 2.5, 5, 10 and 
20 μ M; Bupropion was used at 5, 10, 20 and 40 μ M; Tolbutamide was used at 5, 10, 20 and 40 μ M; 
Dextromethorphan was used at 1.25, 2.5, 5 and 10 μ M; Chlorzoxazone was used at 5, 10, 20 and 40 μ M; 
Midazolam was used at 0.625, 1.25, 2.5 and 5 μ M. Each data point represents the mean of quadruplicate 
determinations.
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Discussion
Plumbago zeylanica L. has been widely used as traditional herbal medicine among many Chinese minorities for 
many years. Meanwhile, the medicinal plant is the main ingredient of Qubai Babuqi Pian (Sinopharm XinJiang 
Pharmaceutical Co., Ltd.) which is used to treat leucoderma in Uighur medicine. Nowadays, herbal medicines, 
especially being consumed along with modern drugs, are increasingly popular when patients are in several dis-
eases or conditions11,14. When they are co-administered over overlapping time periods, the possibility of HDIs 
mediated by CYPs might exist20,21. However, the inhibition effects of plumbagin on CYP activities were rarely 
concerned. Among all CYP isoforms in humans, CYP3A4, CYP2C9, CYP1A2, CYP2E1, CYP2D6 and CYP2B6 
are relative abundant, which accounts about for 40%, 20%, 13%, 10%, 2% and 2% in total CYPs respectively, 
and responsible for metabolism of the majority of clinically prescribed drugs14,22–24. CYP1A2 is involved in the 
metabolism of a variety of clinically using drugs, such as clozapine, tacrine, tizanidine, theophylline, and several 
important endogenous compounds22,24–26. CYP2B6 is responsible for approximately 3–8% of widely used pharma-
ceuticals and also reported to have high expression in breast tumors23,27,28. CYP2C9 contributes to the metabolism 
of not only commonly prescribed drugs which accounts for 10–20%, but also fatty acids, prostanoids and ster-
oid hormones22. CYP2D6 expressing in liver and extrahepatic organs mediates approximately 25% of marketed 
drugs, such as antidepressants and antipsychotics29. Meanwhile, CYP2D6 with decreased activity is implicated in 
Parkinson disease in Caucasian populations29. CYP2E1 as a natural ethanol-inducible enzyme metabolically acti-
vates various carcinogens. Increased CYP2E1 activity is linked to the carcinogenic process30. Furthermore, more 
than 50% of drugs were metabolized by CYP3A4 including antibiotics, antiviral drugs, benzodiazepines, calcium 
channel blockers, statins and immunosuppressive drugs31,32. However, to our knowledge, the inhibition effects of 
plumbagin on these important CYPs have not been reported except for CYP1A2 and CYP3A417. In particular, the 
mechanisms of inhibition of all six CYPs were completely investigated for the first time. The purpose of our work 
was to investigate the effects of plumbagin on the major CYP activities both in human and rat liver and assess the 
potential HDIs involved plumbagin or Plumbago zeylanica L.
To evaluate the potential HDIs, the cocktail approach, frequently used for CYP inhibition studies33–35, has 
been developed for monitoring CYP activities in a single run by LC-MS/MS with high sensitivity and selec-
tivity. According to FDA guidance, classical probe substrates including phenacetin (CYP1A2), bupropion 
(CYP2B1/6), tolbutamide (CYP2C9/11), dextromethorphan (CYP2D1/6), chlorzoxazone (CYP2E1) and mida-
zolam (CYP3A2/4) were selected. The concentrations of probe substrates were close to the Km values of each 
CYP-catalyzed reaction according to published papers16,33. Given that the linear initial rates of metabolites for-
mation for all selected CYPs with minimal substrates depletion and the automatic inactivation of CYPs in 37 °C 
comprehensively, the incubation time was chosen to 20 min. Moreover, the microsomal protein concentration 
in HLMs was 0.5 mg/ml, which was the most frequently employed, and high protein concentrations ought to be 
avoided because of the possibility of protein binding18.
To investigate whether inhibition of CYPs by plumbagin was time-dependent, time-dependent inhibition 
assays were performed with various plumbagin concentrations close to IC25, which was the most sensitive point 
for detecting a time-dependent inhibitor36,37. Too low concentrations of plumbagin may miss inactivation, but 
too high concentrations of plumbagin may cause much reversible inhibition to make the effect of time-dependent 
inhibition not obvious36. Meanwhile, considering not only automatic inactivation of some CYPs but also weak 
inhibitors which could not be identified within a short inactivation time, 20 min was used for this time-dependent 
inhibition assays. From Fig. 2, the activity of CYP2D6 in HLMs decreased slightly in a time-dependent manner 
without any inhibitor, which could be explained for easily automatic inactivation of CYP2D6 in HLMs. On the 
other hand, the inhibition effects on several CYPs by plumbagin were reduced with pre-incubation with NADPH, 
which could be due to metabolic depletion of plumbagin leading to diminished inhibitory capability36,38. 
Therefore, no time-dependent inhibition was observed in both HLMs and RLMs, which showed reversible inhi-
bition of CYP1A2, CYP2B1/6, CYP2C9/11, CYP2D1/6, CYP2E1 and CYP3A2/4 by plumbagin.
The present study showed that the types of inhibition by plumbagin were mixed inhibition on CYP2B6, 
CYP2C9, CYP2D6, CYP2E1 and CYP3A4, but non-competitive for CYP1A2 in HLMs and the Ki values were 
1.62 μ M, 2.16 μ M, 1.46 μ M, 0.65 μ M, 0.88 μ M and 0.15 μ M, respectively. Correspondingly, mixed inhibition on 
CYP1A2 and CYP2D1, but competitive for CYP2B1, CYP2C11 and CYP2E1 were observed in RLMs and the Ki 
values were 2.64 μ M, 9.49 μ M, 9.93 μ M, 7.85 μ M, and 6.28 μ M, respectively. Thus, plumbagin was a potent inhib-
itor on the above CYPs in both humans and rats.
Based on the inhibition results of HLMs and RLMs, some differences should be noticed such as the types of 
CYP inhibition and inhibitory intensity. The Ki values of inhibition on CYPs by plumbagin in HLMs are gener-
ally lower than those in RLMs. It may be attributed to variations in CYP levels, inducibilities and the existence 
of different CYP isoforms of the same protein family or subfamily in different species39. For example, CYP2C11 
accounts for about 50% in total rat CYPs while human CYP2C9 being a homologue of the rat CYP2C11 with 77% 
homology only accounts for 20% of total human CYPs40. In addition, the enzyme inhibition kinetic of CYP3A2 
disagreed with the classical Michaelis–Menten kinetics in RLMs, but the enzyme inhibition kinetic of CYP3A4 
in HLMs conformed to that when the concentrations of midazolam were no more than 5 μ Μ . The differences 
between CYP3A2 and CYP3A4 could also be a reflection of species differences. Consequently, extrapolating 
results from animals to humans should be cautious.
As mentioned above, when investigating the enzyme inhibition kinetic of CYP3A2, we found it did not con-
form to the classical Michaelis–Menten kinetics in RLMs. In fact, metabolic activation was achieved by incu-
bation of plumbagin in the presence of CYP3A2 when the concentrations of midazolam are less than 5 μ Μ in 
RLMs41. In this report, however, the unusual effects of plumbagin on CYP3A2 could be explained using an atyp-
ical kinetics model. Atypical Michaelis–Menten kinetics including substrate inhibition, partial inhibition, activa-
tion, auto-activation and biphasic metabolism has been demonstrated for some CYP3A-mediated reactions42,43. 
In this study, CYP3A2 displayed auto-activation kinetics. Multisite hypothesis was a possible mechanistic model 
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Figure 4. Primary Lineweaver–Burk plot, the secondary plot for Ki and the secondary plot for αKi in the 
inhibition of CYP-mediated probe substrate metabolism by various concentrations of plumbagin (0 , 1 , 
2 , 5 , 10 ♦ μM) in rat liver microsomes. Phenacetin was used at concentrations of 2.5, 5, 10 and 20 μ M; 
Bupropion was used at 5, 10, 20 and 40 μ M; Tolbutamide was used at 5, 10, 20 and 40 μ M; Dextromethorphan 
was used at 1.25, 2.5, 5 and 10 μ M; Chlorzoxazone was used at 5, 10, 20 and 40 μ M. Each data point represents 
the mean of six rats.
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of atypical kinetics. CYP3A enzyme except for two or more midazolam-binding sites contains an activator bind-
ing site which is closely related to the substrate binding sites42. Plumbagin might lead to metabolic activation by 
binding to the activator binding sites. These speculations still need to be further proved by experiments.
Previous pharmacokinetic study of plumbagin by oral administration (100 mg/kg) in rats showed that the 
peak concentration (Cmax), half-life (t1/2) and area under the curve (AUC) of plumbagin in the plasma was 
0.35 μ g/ml (1.86 μ M), 1028 min and 271.9 min* μ g/ml, respectively3. Therefore, the rat plasma concentrations 
were close to the IC50 and Ki values determined in this study, thus suggesting plumbagin could quite probably 
decrease the activities of CYP1A2, CYP2B1, CYP2C11, CYP2D1, CYP2E1 and CYP3A2 in vivo. In fact, these CYP 
homologues in humans are responsible for 80% of the CYP-mediated metabolism including a number of drugs 
with narrow therapeutic ranges. Therefore the potential HDIs should be brought to attention and further studies 
in vivo are needed to confirm the interactions of plumbagin with CYP isoforms in humans.
In conclusion, the data in this study demonstrated that plumbagin exhibited potently broad-spectrum 
inhibitory effects toward CYP enzymes including CYP1A2, CYP2B1/6, CYP2C9/11, CYP2D1/6, CYP2E1 and 
CYP3A2/4 with lower Ki values in both human and rat liver. In particular, plumbagin was not only a mixed inhib-
itor of CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4, but also a non-competitive inhibition of CYP1A2 in 
humans. These results provided useful guidance for safe and effective usage of plumbaign in clinic, especially in 
combination with other drugs.
Methods
Materials and chemicals. Pooled human liver microsomes (n = 20) were obtained from Corning Gentest 
Corporation (Woburn, MA, USA) and stored at − 150 °C until use. All the experimental procedures involv-
ing humans have been carried out in accordance with The Code of Ethics of the World Medical Association 
(Declaration of Helsinki) guidelines. Phenacetin, bupropion, tolbutamide, dextromethorphan, midazolam, 
3-acetamidophenol (internal standard), chlorpropamide (internal standard), glucose 6-phosphate (G6P), glu-
cose 6-phosphate dehydrogenase (G6PDH), β -nicotinamide adenine dinucleotide phosphate (NADP) and 
tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl) were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). Chlorzoxazone was purchased from Alfa Aesar (Massachusetts, USA). 4-acetamidophenol, 
hydroxybupropion, 4-hydroxytolbutamide, dextrorphan, 6-hydroxychlorzoxazone and 1-hydroxymidazolam 
were obtained from Toronto Research Chemical (North York, Canada). Mebendazole (internal standard) was 
obtained from Aladdin Industrial Co. (California, USA). Plumbagin (purity > 98%) was purchased from Dalian 
Meilun Biotech Co., Ltd (Dalian, China). Acetonitrile and methanol (all HPLC grade) were purchased from 
Fisher Chemicals (Leicester, UK). Formic acid (HPLC grade) was purchased from TEDIA (Ohio, USA). Distilled 
water was purified in a Millipore system Milli Q (Millipore Corp., Bedford, MA, USA).
Animals. Male Sprague-Dawley rats (200–250 g) were supplied by National Rodent Laboratory Animal 
Resources, Shanghai Branch of China. The animals were kept in a specific pathogen-free facility and with access 
to rodent cubes and sterile water, with 12 h light-dark cycles. All the methods in animals were carried out in 
accordance with the National Institutes of Health standards established in the ‘Guidelines for the Care and Use of 
Experimental Animals’. All experimental protocols in animals were approved by the Ethics Committee on Animal 
Experimentation of East China Normal University (Shanghai, China).
Figure 5. Sigmoidal auto-activation kinetics curve of CYP3A2 by various concentrations of plumbagin 
(0 , 1 , 2 , 5 , 10 ♦ μM) in rat liver microsomes. Midazolam was used at concentrations of 2.5, 5, 10, 20, 
40 and 80 μ M. Insets show the corresponding Eadie-Hofstee plots for CYP3A2 kinetic profile.
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Preparation of rat liver microsomes. In this study, the rats were fasted overnight and killed by cervi-
cal dislocation before removal of the liver. The liver was excised, rinsed with ice-cold saline (0.9% NaCl w/v), 
weighed and homogenized in a 0.05 mM Tris/KCl buffer (pH 7.4). Subsequently, the homogenate was centrifuged 
at 10,000 × g at 4 °C for 30 min. The supernatant was then centrifuged at 105,000 × g at 4 °C for 60 min. The pellet 
was reconstituted with 0.05 mM Tris/KCl buffer (pH 7.4) and stored at − 150 °C until use. The protein concentra-
tion of the liver microsomes was determined by a protein quantitative assay using bicinchoninic acid22.
Microsomal incubation. Microsomal incubation was carried out at 37 °C in a mixture of 200 μ l in 0.05 M 
Tris/HCl buffer (pH 7.4) consisting of pooled HLMs (0.5 mg/ml) or RLMs (1 mg/ml) and an NADPH-regenerating 
system including MgCl2 (5 mM), G6P (10 mM), G6PDH (0.4 U/ml) and NADP (1 mM). Substrates were added 
into the incubation mixture and obtained the final concentrations (10 μ M phenacetin for CYP1A2, 20 μ M bupro-
pion for CYP2B1/6, 20 μ M tolbutamide for CYP2C9/11, 5 μ M dextromethorphan for CYP2D1/6, 20 μ M chlor-
zoxazone for CYP2E1 and 10 μ M midazolam for CYP3A2/4), which were close to Km respectively. The proportion 
of organic solvent was not higher than 1% (v/v) in the incubation mixture18,44. After pre-incubation for 5 min, the 
reaction was initiated by addition of NADP. Incubations were performed for 20 min, stopped by adding 200 μ l 
ice-cold acetonitrile. And then 20 μ l internal standard solution was added (3-acetamidophenol 2 μ g/ml, chlor-
propamide 2 μ g/ml and mebendazole 2 μ g/ml). The solution was mixed thoroughly for 3 min and centrifuged for 
10 min at 16,000 × g at 4 °C. The supernatant (60 μ l) was transferred to autosampler vials, and 2 μ l was injected 
into LC-MS/MS system.
Determination of IC50 values for inhibition. The IC50 (concentration of inhibitor to cause 50% inhibition 
of original enzyme activity) values were determined with the same incubation condition above. The specific con-
centrations of plumbagin were ranged from 0.1 μ M to 50 μ M. The IC50 values were calculated by plotting relative 
activities over the logarithm of plumbagin concentrations using GraphPad Prism 5.0 (GraphPad software Inc., 
CA, USA).
Mechanism of inhibition of CYPs by plumbagin. To explore the time-dependent inhibition of plumbagin 
on CYPs, inactivation incubation containing plumbagin whose final concentration close to IC25 (concentration of 
inhibitor to cause 25% inhibition of original enzyme activity)37, pooled HLMs (0.5 mg/ml) or RLMs (1 mg/ml), 
MgCl2 (5 mM), G6P (10 mM), G6PDH (0.4 U/ml), NADP (1 mM) and 0.05 M Tris/HCl buffer (pH 7.4) was per-
formed for 0, 5, 10 and 20 min at 37 °C. Cocktail probe substrates were then added and incubated for 20 min. 
Reactions were stopped with 200 μ l ice-cold acetonitrile. The samples were treated according to the microsomal 
incubation method and then injected into LC-MS/MS for analysis.
Kinetic studies were performed for determining the types of inhibition on CYP by plumbagin. Pooled HLMs 
(0.5 mg/ml) or RLMs (1 mg/ml) with plumbagin (1 μ M, 2 μ M, 5 μ M and 10 μ M) were incubated in 0.05 M Tris/
HCl buffer (pH 7.4) for 20 min at 37 °C. A series of concentrations for cocktail probe substrates were used: 
2.5–20 μ M phenacetin for CYP1A2; 5–40 μ M bupropion for CYP2B1/6; 5–40 μ M tolbutamide for CYP2C9/11; 
1.25–10 μ M dextromethorphan for CYP2D1/6; 5–40 μ M chlorzoxazone for CYP2E1; 2.5–80 μ M midazolam for 
CYP3A2; and 0.625–5 μ M midazolam for CYP3A4. Enzyme kinetics as well as statistical analysis were performed 
using GraphPad Prism 5.0.
LC-MS/MS analysis. LC-MS/MS is a powerful tool to detect the concentrations of several CYP substrates 
and metabolites in a short time, and to calculate the enzymatic reaction rate, which is used to evaluate the cor-
responding CYP enzyme activities. In this study, an Agilent 1290 LC system consisting of a degasser, a binary 
pump, an autosampler and a thermostatic column compartment was coupled with a 6460 triple-quadrupole mass 
Analyte Ionization mode Precursor ion (m/z) Product ion (m/z) Fragmentor (V) Collision energy (eV)
Phenacetin ESI+ 180.1 110.2 110 21
4-acetamidophenol ESI+ 152.1 110.1 90 15
Bupropion ESI+ 240.1 184.1 90 8
Hydroxybupropion ESI+ 256.1 238.1 70 8
Tolbutamide ESI− 269.2 170.0 100 12
4-hydroxytolbutamide ESI− 285.2 186.0 100 12
Dextromethorphan ESI+ 272.3 147.1 150 33
Dextrorphan ESI+ 258.1 157.1 150 42
Chlorzoxazone ESI− 168.0 132.0 110 20
6-hydroxychlorzoxazone ESI− 184.1 120.0 90 17
Midazolam ESI+ 326.1 291.0 170 28
1-hydroxymidazolam ESI+ 342.1 324.0 130 20
3-acetamidophenol (IS) ESI+ 152.1 93.0 80 26
Chlorpropamide (IS) ESI− 275.1 190 100 11
Mebendazole (IS) ESI+ 296.1 264.1 150 22
Table 2.  Analytical parameters for the individual substrate, metabolite and internal standard (IS).
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spectrometer (Agilent Technologies, USA), which was equipped with an Agilent Jet Stream electrospray ioniza-
tion (ESI) source and operated with Agilent MassHunter version 5.0.280.1 software (Agilent Technologies, USA). 
Figure 6. Representative multiple reaction monitoring chromatograms of CYP probe substrates, 
metabolites and internal standards. 
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Chromatography separation was performed on a Phenomenex Kinetex XB-C18 column (100 × 3.00 mm, 2.6 μ M) 
protected by a Phenomenex C18 guard column (Torrance, CA, USA). The mobile phase consisted of solvent A 
(0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) using gradient elution at a flow rate 
of 0.3 mL/min. The optimum condition for elution was as follows: 0–2.2 min, 10–11% B; 2.2–8.5 min, 11–90% B; 
8.5–9 min, 90–92% B; 9–9.3 min, 92% B; 9.3–9.6 min, 92–10% B; 9.6–11.5 min, 10% B. The temperature of column 
oven was maintained at 30 °C, and the injection volume was 2 μ L. The mass spectrometer was operated in the 
positive/negative ion-switching ESI mode, and the detection of the ions was performed in the multiple reaction 
monitoring (MRM) mode. Each MRM transition and the compound dependent parameters are presented in 
Table 2. MS/MS conditions were optimized as follows: gas temperature, 350 °C; gas flow, 10 L/min; nebulizer, 
35 psi; sheath gas temperature, 350 °C; sheath gas flow, 11 L/min; collision gas (N2), 1.6 MPa. A divert valve was 
used to divert the eluent to waste from 0 to 2 min, 10 to 11.5 min, and to MS from 2 to 10 min. Representative 
multiple reaction monitoring chromatograms of analytes were shown in Fig. 6.
Data analysis. All data were presented as mean ± SD. The IC50 values were fitted by non-linear regression 
analysis using GraphPad Prism 5.0. The kinetic parameters were obtained by fitting velocity data to kinetic 
models (Michaelis-Menten) using GraphPad Prism 5.0. The Lineweaver-Burk Plot (the reciprocal of reaction 
velocities versus the reciprocal of substrates concentrations) was used to determine the quality of fit to a specific 
inhibition model. The inhibition constant (Ki) was obtained by a secondary plot using the slopes of the primary 
Lineweaver-Burk Plot (Km/Vmax versus inhibitor concentrations). α Ki was obtained from a secondary plot using 
the y-intercepts of the Lineweaver-Burk plot (1/Vmax versus inhibitor concentrations). All results were analyzed 
in quadruplicate. One-way analysis of variance was used to estimate the significance of differences. There was 
statistical significance between control and test groups if p < 0.05.
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